{"id":"ga-psma-11","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Radiation exposure (expected from PET imaging)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ga-PSMA-11 consists of gallium-68, a positron-emitting radioisotope, conjugated to a small molecule ligand that specifically targets PSMA, a transmembrane protein highly expressed on prostate cancer cells. When injected intravenously, it accumulates at sites of PSMA expression and emits positrons that are detected by PET imaging, allowing visualization and localization of prostate cancer lesions. This enables improved staging, restaging, and monitoring of prostate cancer patients.","oneSentence":"Ga-PSMA-11 is a gallium-68 labeled imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable PET imaging detection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:40.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"PET imaging of PSMA-positive lesions in men with prostate cancer"},{"name":"Staging and restaging of prostate cancer"}]},"trialDetails":[{"nctId":"NCT05658003","phase":"PHASE2","title":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-05","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":63},{"nctId":"NCT06288113","phase":"PHASE2","title":"Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":40},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT06216249","phase":"PHASE2","title":"Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":"Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8","enrollment":90},{"nctId":"NCT07089550","phase":"","title":"PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-04-02","conditions":"PSMA Positive Tumors or Tumor Tissues, Prostate Cancer Metastatic","enrollment":1300},{"nctId":"NCT05670106","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-16","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":62},{"nctId":"NCT05160597","phase":"EARLY_PHASE1","title":"Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2022-01-13","conditions":"Prostate Carcinoma","enrollment":30},{"nctId":"NCT06335914","phase":"NA","title":"Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-04-03","conditions":"Advanced Prostate Cancer","enrollment":30},{"nctId":"NCT05176223","phase":"PHASE2","title":"68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-01-30","conditions":"Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":29},{"nctId":"NCT06099093","phase":"PHASE4","title":"Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-04-01","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma","enrollment":30},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":15},{"nctId":"NCT07365397","phase":"NA","title":"Imaging Characteristics of Different ⁶⁸Ga-PSMA Probes in Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-19","conditions":"Prostate Cancer","enrollment":9},{"nctId":"NCT06444412","phase":"PHASE2","title":"An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-12","conditions":"WHO Grade 3 Glioma, WHO Grade 4 Glioma","enrollment":25},{"nctId":"NCT04777071","phase":"PHASE2","title":"An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-05-17","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":141},{"nctId":"NCT06531499","phase":"PHASE1","title":"A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-11","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":106},{"nctId":"NCT07301827","phase":"NA","title":"Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-01","conditions":"Renal Cell Carcinoma","enrollment":66},{"nctId":"NCT07150715","phase":"PHASE2","title":"Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-12-12","conditions":"Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma","enrollment":107},{"nctId":"NCT04176497","phase":"PHASE2","title":"PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2020-07-16","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT04762888","phase":"PHASE2","title":"68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-02-24","conditions":"Hepatocellular Carcinoma","enrollment":52},{"nctId":"NCT04838613","phase":"PHASE3","title":"Study of Diagnostic Performance of [18F]CTT1057 in BCR","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-30","conditions":"Prostatic Neoplasms, Prostate Cancer, Recurrence","enrollment":190},{"nctId":"NCT06999837","phase":"NA","title":"[68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2025-09-23","conditions":"HCC - Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06265272","phase":"","title":"Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-12-10","conditions":"Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension","enrollment":45},{"nctId":"NCT06852820","phase":"PHASE2","title":"68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)","status":"NOT_YET_RECRUITING","sponsor":"Melissa Lumish","startDate":"2025-09-22","conditions":"Liver Cancer, Hepatocellular Carcinoma, Metastatic Liver Cancer","enrollment":10},{"nctId":"NCT06521775","phase":"PHASE2","title":"An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-08-12","conditions":"Metastatic Adenoid Cystic Carcinoma","enrollment":6},{"nctId":"NCT06200103","phase":"PHASE2","title":"Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-05-03","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":236},{"nctId":"NCT07052214","phase":"PHASE3","title":"PSMA PET Combined With MRI for the Detection of PCa","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-08-18","conditions":"PCA, Prostate Cancer, Prostatic Neoplasm","enrollment":204},{"nctId":"NCT04147494","phase":"EARLY_PHASE1","title":"Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-11-05","conditions":"Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma","enrollment":29},{"nctId":"NCT05547386","phase":"PHASE3","title":"68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-05-09","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":163},{"nctId":"NCT06067269","phase":"PHASE2","title":"Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-03-28","conditions":"Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8","enrollment":95},{"nctId":"NCT06655064","phase":"","title":"Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-01-30","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":120},{"nctId":"NCT03582774","phase":"PHASE3","title":"Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-07-12","conditions":"Recurrent Prostate Carcinoma","enrollment":193},{"nctId":"NCT04484701","phase":"","title":"[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2021-02-01","conditions":"Prostatic Neoplasm, Prostatic Cancer","enrollment":1574},{"nctId":"NCT04597411","phase":"PHASE1","title":"Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer","status":"RECRUITING","sponsor":"Endocyte","startDate":"2021-04-01","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":99},{"nctId":"NCT06044857","phase":"PHASE1","title":"PSMA PET Response Guided SabR in High Risk Pca","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-03-07","conditions":"Prostate Adenocarcinoma","enrollment":20},{"nctId":"NCT06835244","phase":"","title":"Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms","status":"ENROLLING_BY_INVITATION","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2021-09-17","conditions":"PSMA Positive Tumors or Tumor Tissues, Cancer","enrollment":1000},{"nctId":"NCT04750473","phase":"PHASE1","title":"Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-07-16","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma","enrollment":20},{"nctId":"NCT04716725","phase":"PHASE2","title":"68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hope","startDate":"2021-09-28","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":15},{"nctId":"NCT04310540","phase":"EARLY_PHASE1","title":"PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-06-05","conditions":"Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT02952469","phase":"EARLY_PHASE1","title":"Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2016-07-14","conditions":"Prostatic Neoplasms","enrollment":22},{"nctId":"NCT05847348","phase":"PHASE3","title":"68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2023-07-19","conditions":"Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma","enrollment":110},{"nctId":"NCT06462508","phase":"EARLY_PHASE1","title":"Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-04-20","conditions":"Prostate Cancer, PET/CT","enrollment":30},{"nctId":"NCT04243941","phase":"PHASE2","title":"PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer","status":"WITHDRAWN","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-11-29","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT05034562","phase":"PHASE2","title":"Gallium-68 PSMA-11 PET in Participants With Prostate Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-09-26","conditions":"Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT06259123","phase":"PHASE2","title":"Neoadjuvant PSMA-RLT in Oligometastatic PCa","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-02-01","conditions":"Prostate Cancer","enrollment":10},{"nctId":"NCT06241391","phase":"NA","title":"Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2024-02","conditions":"Glioma, Astrocytoma, Anaplastic Astrocytoma","enrollment":35},{"nctId":"NCT04264208","phase":"PHASE2","title":"HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer","status":"TERMINATED","sponsor":"Andrei Iagaru","startDate":"2020-02-05","conditions":"Prostate Cancer","enrollment":4},{"nctId":"NCT03949517","phase":"PHASE1, PHASE2","title":"68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy","status":"COMPLETED","sponsor":"Andrei Iagaru","startDate":"2019-04-09","conditions":"Prostate Cancer","enrollment":14},{"nctId":"NCT05197257","phase":"PHASE3","title":"68Ga-PSMA-11 PET in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-09-29","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":39},{"nctId":"NCT05111314","phase":"EARLY_PHASE1","title":"Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2022-02-11","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT05798273","phase":"NA","title":"(68^Ga)-GaPSMA-11 PET/MR-imaging of Malignant Intra-axial Brain Tumors","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2020-09-01","conditions":"Malignant Brain Tumors","enrollment":12},{"nctId":"NCT04614363","phase":"PHASE1, PHASE2","title":"68 Ga-PSMA for High Risk Prostate Cancer","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2020-10-13","conditions":"Prostate Cancer, High Risk","enrollment":80},{"nctId":"NCT05558956","phase":"EARLY_PHASE1","title":"Total Body PET-CT Imaging of Prostate Cancer Using Illuccix","status":"UNKNOWN","sponsor":"BAMF Health","startDate":"2022-11-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":100},{"nctId":"NCT05955677","phase":"EARLY_PHASE1","title":"Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis","status":"UNKNOWN","sponsor":"Anhui Provincial Hospital","startDate":"2023-07-10","conditions":"Prostate Cancer, PET/CT","enrollment":100},{"nctId":"NCT04216134","phase":"PHASE1","title":"68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2019-12-12","conditions":"Biochemically Recurrent Prostate Carcinoma","enrollment":19},{"nctId":"NCT05896449","phase":"NA","title":"Predictive Values of Preoperative [68Ga]Ga-PSMA-11 PET/CT in Patients With Suspected Brain Tumours of Glial Origin","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2020-06-01","conditions":"Glioma, Malignant, Glioma Glioblastoma Multiforme","enrollment":49},{"nctId":"NCT03368547","phase":"NA","title":"68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2016-12-12","conditions":"Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7","enrollment":400},{"nctId":"NCT04854369","phase":"","title":"68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly)","status":"NO_LONGER_AVAILABLE","sponsor":"Tulane University","startDate":"","conditions":"Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant","enrollment":""},{"nctId":"NCT04976257","phase":"EARLY_PHASE1","title":"Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion","status":"COMPLETED","sponsor":"Ryan Kohlbrenner, MD","startDate":"2021-10-13","conditions":"Prostate Adenocarcinoma, Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8","enrollment":5},{"nctId":"NCT04928820","phase":"PHASE2","title":"68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-06-16","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma","enrollment":22},{"nctId":"NCT03857087","phase":"","title":"68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-04-02","conditions":"Ovarian Carcinoma","enrollment":7},{"nctId":"NCT04279561","phase":"PHASE1","title":"Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-04-16","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8","enrollment":9},{"nctId":"NCT03982407","phase":"EARLY_PHASE1","title":"68 Ga PSMA PET/MRI for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Ajit H. Goenka, MD","startDate":"2019-06-27","conditions":"Hepatocellular Carcinoma","enrollment":5},{"nctId":"NCT02673151","phase":"PHASE2, PHASE3","title":"68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment","status":"COMPLETED","sponsor":"Andrei Iagaru","startDate":"2017-05-20","conditions":"Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma","enrollment":61},{"nctId":"NCT04050215","phase":"PHASE2","title":"68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-04-02","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":937},{"nctId":"NCT02940262","phase":"PHASE3","title":"Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2016-09-15","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma","enrollment":1138},{"nctId":"NCT03463889","phase":"PHASE2","title":"Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2018-03-19","conditions":"Thyroid Gland Carcinoma","enrollment":12},{"nctId":"NCT04377152","phase":"","title":"Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer","status":"APPROVED_FOR_MARKETING","sponsor":"University of California, San Francisco","startDate":"","conditions":"Prostate Cancer, Prostate, Prostate Adenocarcinoma","enrollment":""},{"nctId":"NCT04282824","phase":"EARLY_PHASE1","title":"Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-06-05","conditions":"Prostate Carcinoma","enrollment":14},{"nctId":"NCT03515577","phase":"PHASE2","title":"Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-04-12","conditions":"Recurrent Prostate Carcinoma","enrollment":50},{"nctId":"NCT04462926","phase":"NA","title":"Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2020-09-20","conditions":"Prostate Cancer, Prostatic Neoplasm, Urogenital Neoplasms","enrollment":100},{"nctId":"NCT02282137","phase":"PHASE2","title":"68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer","status":"UNKNOWN","sponsor":"Ebrahim Delpassand","startDate":"2015-05","conditions":"Prostate Cancer","enrollment":208},{"nctId":"NCT04159090","phase":"NA","title":"Head- to Head Comparison of [68Ga]Ga-PSMA-11 With [18F]PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2018-01-15","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT02488070","phase":"PHASE1, PHASE2","title":"68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"Stanford University","startDate":"2015-06","conditions":"Recurrent Prostate Carcinoma","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ga-PSMA-11","genericName":"Ga-PSMA-11","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ga-PSMA-11 is a gallium-68 labeled imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable PET imaging detection. Used for PET imaging of PSMA-positive lesions in men with prostate cancer, Staging and restaging of prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}